#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need accurate information about cannabis addiction potential and long-term safety to counsel patients honestly about risks, particularly regarding cannabis use disorder which affects approximately 9% of users and higher rates in adolescents. Understanding the evidence on dependence liability and chronic effects informs clinical decision-making for both recreational users and patients considering cannabis for medical conditions. Patients deserve clear guidance about addiction risk and long-term consequences to make informed choices about their own cannabis use.
Cannabis use disorder affects approximately 9% of users overall and up to 17% among those initiating use in adolescence, indicating genuine addiction potential that clinicians should assess during substance use screening. While cannabis is often perceived as safe, regular long-term use carries documented risks including cognitive impairment, motivational syndrome, psychosis in vulnerable populations, and respiratory complications in smoked forms, though these risks vary by individual susceptibility and route of administration. The addictive liability of cannabis is lower than alcohol or opioids but higher than many patients believe, particularly with modern high-potency products and concentrated forms that deliver significantly higher THC levels than historical cannabis. Clinicians should counsel patients that long-term safety remains incompletely characterized, especially regarding effects on adolescent brain development, reproductive health, and driving safety, while recognizing that some patients may benefit from cannabis for specific conditions despite these risks. The practical takeaway for clinicians is to conduct thorough substance use histories, screen for cannabis use disorder symptoms, and provide evidence-based counseling that acknowledges both addiction risk and potential therapeutic applications rather than defaulting to categorical safety or danger messaging.
“The evidence shows that while cannabis carries lower addiction potential than many other substances, psychological dependence is real and occurs in a meaningful subset of users, particularly with daily use and high-THC products. Long-term safety data remain incomplete, especially regarding cognitive effects in developing brains and respiratory impacts with smoking, so we need to counsel patients honestly about what we know, what we don’t, and encourage individualized risk assessment rather than blanket recommendations.”
🧠 While cannabis is often perceived as non-addictive compared to other substances, clinical evidence demonstrates that regular use carries genuine risks of psychological dependence, with approximately 9% of users (and up to 17% of adolescent users) meeting criteria for cannabis use disorder. Long-term use has been associated with cognitive impairment, altered brain development in adolescents, increased psychotic symptoms in vulnerable populations, and potential respiratory effects, though the research base remains limited by funding constraints and the drug’s federal scheduling, which complicates rigorous long-term studies. The heterogeneity of cannabis products, inconsistent cannabinoid concentrations, and highly variable individual susceptibility make it difficult to generalize safety profiles across users and consumption methods. Clinicians should routinely screen for cannabis use during substance use assessments, particularly in adolescents and young adults, and counsel patients seeking long-term use about documented cognitive and psychiatric risks rather than
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
